Peter Attia MD406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment
Peter Attia MD
An accidental path into headache medicine 0:00
Dr. Brian Grosberg explains that headache is one of the most common neurologic symptoms, yet medical schools and even neurology residencies devote only a few hours to it. His own specialization happened by chance during his first year of residency, when he treated a litigator disabled by a migraine lasting six weeks straight. Consulting with a specialist who became his mentor, he began seeing patients after his hospital shifts, sometimes after being on call for over 30 hours, and this informal apprenticeship became the foundation for his later formal fellowship training in headache medicine, a field with only a limited number of dedicated training programs nationwide.
Why headache is hard to diagnose 6:31
Peter Attia points out that headaches, unlike a torn ligament, leave no visible marker on an MRI or CT scan to confirm what is wrong. Grosberg agrees, noting that headache is simply the perception of pain in the head, face, scalp, or neck, and that the list of possible causes is one of the longest in medicine, with over 300 recognized types. The International Classification of Headache Disorders divides them into primary headaches, which are their own syndrome not caused by another condition, and secondary headaches, which result from an underlying issue. The three major primary headaches are migraine, tension-type headache, and cluster headache. Secondary headaches usually involve pathology like a tumor or aneurysm, but not always; overusing pain medication or withdrawing from caffeine can also trigger secondary headaches without any dangerous underlying cause.
Tension-type versus migraine 10:00
Tension-type headache is the most common headache people experience, typically mild to moderate, affecting both sides of the head, not throbbing, and lacking the combination of nausea with light and sound sensitivity. It can last from 30 minutes to a week but rarely stops someone from functioning. Migraine, by contrast, is the leading reason people seek care from a doctor or emergency room. To be diagnosed, a person needs at least five lifetime attacks lasting 4 to 72 hours, along with two of four features: pain that is often one-sided (though up to 40 percent of migraine sufferers feel pain on both sides), pulsating quality, avoidance of activity, and either light and sound sensitivity or nausea and vomiting.
The phases and aura of migraine 15:30
Migraine unfolds in phases that can overlap. The premonitory phase, sometimes called the calm before the storm, brings yawning, food cravings, tiredness, irritability, light sensitivity, or neck stiffness, appearing hours or even days before the headache itself. About a quarter to a third of people with migraine experience an aura, a temporary neurologic phenomenon caused by a wave of nerve cell excitability, called cortical spreading depolarization, that starts in the back of the brain and spreads gradually over 5 to 60 minutes. Because the back of the brain houses the visual cortex, the most common aura involves visual disturbances like zigzag lines or blind spots. Unlike a stroke or TIA, where symptoms hit at their worst instantly, migraine aura evolves gradually, often moves sequentially through visual, sensory, language, or motor symptoms, and typically affects only one side, all of which help distinguish it from a dangerous cerebrovascular event.
Scale of the problem and hormonal links 20:00
Migraine affects roughly 12 percent of the world's population, about one billion people, including around 45 million in the United States, and costs billions of dollars through both absenteeism and the harder-to-measure problem of presenteeism, where people show up to work but function at reduced capacity. Women are affected three times more often than men, pushing the rate among women to roughly 18 percent. Only about 50 fellowship-trained headache neurologists graduate each year, far short of what the demand requires. Migraine also splits into episodic migraine, fewer than 15 headache days a month, and chronic migraine, 15 or more days a month, which affects about 1 to 2 percent of the population. Hormones and genetics both play a role: a family history raises risk, and migraine frequency shifts around puberty, menstruation, pregnancy, lactation, and menopause. About two-thirds of women notice a link between migraine and their period, with a smaller group experiencing pure menstrual migraine tied only to menstruation, while about half experience menstrual-related migraine that also occurs at other times of the month.
Estrogen decline and migraine timing 28:31
Studies dating back to the 1970s connect migraine to the natural drop in estrogen during the late luteal phase, but more recent research shows it is specifically the rapid rate of that decline, not the decline itself, that is unique to women who experience migraine. Interestingly, the sharp estrogen drop that happens right after ovulation does not carry the same elevated migraine risk, which points to something particular about the speed and degree of the late luteal fall. Estrogen also affects serotonin transmission, and serotonin levels are known to drop during migraine attacks and rise again during recovery, a pattern that helped lead to the development of triptan medications.
Hormone therapy is unpredictable 31:30
Giving women physiologic estrogen around the time of the expected crash has been tried, but outcomes vary widely: some women improve, some see no change, and some on combined hormonal contraceptives actually get worse. Because predicting who will respond is so difficult, treatment often works best through a collaborative model where a headache specialist and a gynecologist map out an individualized hormonal plan together.
Genetics and a possible evolutionary angle 33:00
Migraine is highly hereditary, though not tied to a single gene, it is polygenic, meaning many genes contribute. People with migraine simply have a more hyperexcitable nervous system, so they are not exposed to more light, sound, or stress, but they perceive and react to it more intensely. One colleague has speculated an evolutionary upside, particularly for women as caregivers, in sensing incoming danger like storms, and there is also a broader question about whether heightened neural sensitivity relates to the greater multitasking demands often placed on women.
Triggers, diaries, and menopause complications 38:30
Triggers do not cause migraine, they only set it off in people already biologically predisposed, and it usually takes a combination of two or more triggers, such as weather changes, post-stress letdown, or certain foods, to bring on an attack. A detailed headache diary, kept over months, is described as one of the most valuable tools both for patients and clinicians, especially for confirming a menstrual-related pattern, which requires the association to show up in at least two out of three cycles. Migraine does not simply vanish at menopause: roughly two-thirds of women improve after the perimenopausal transition, but 10 to 20 percent stay the same or worsen, and hormone therapy dosing during this period can be delicate, sometimes requiring less than a standard therapeutic dose to help without making things worse.
The many phases of a migraine attack 41:30
A migraine attack can include a premonitory phase, sometimes called the calm before the storm, followed in about a quarter to a third of people by an aura, then the pain phase itself, which often comes with light and sound sensitivity, nausea, and autonomic symptoms like eye tearing or nasal congestion caused by involvement of the parasympathetic nervous system and the trigeminal nerve. These nasal and eye symptoms are frequently mistaken for a sinus problem, even though a sinus headache is not a real diagnostic category. After the pain resolves, many people enter a postdrome phase, feeling hungover rather than back to normal, which can last hours or even a couple of days, and clinic-based studies suggest this postdrome affects somewhere between 60 percent and the high 80s percent of patients. There is also an interictal burden, the anxiety and planning disruption that happens between attacks simply from not knowing when the next one will strike.
Tension headache basics 45:31
Tension-type headache is the most common headache overall, occurring in a lifetime incidence high enough to affect a large share of the population, and unlike migraine it is roughly evenly split between men and women. It typically brings mild to moderate pain without light or sound sensitivity, often involving the muscles and nerves around the head and neck, and both genetic and environmental factors contribute, alongside tenderness in the muscles surrounding the skull. Despite its name, it is not simply caused by stress, and it can respond to something as simple as over-the-counter Tylenol.
Cluster headache defining features 47:00
Cluster headache is rare compared to migraine and tension headache but ranks among the most painful conditions known, with one patient describing it as like giving birth to a hundred babies at once without an epidural. It affects men more than women, at roughly a 3-to-4-to-1 ratio, and tends to follow a circannial or circadian pattern, often clustering around the longest and shortest days of the year, in January, February, July, and August. Attacks are almost always on one side of the head, build to peak intensity within 5 to 15 minutes, and last from 15 minutes up to 3 hours, described as stabbing or boring in nature. About 97 percent of patients show visible signs during an attack, such as a drooping eyelid, eye tearing or redness, and nasal congestion on the affected side, and about 90 percent feel a restlessness that makes them unable to sit still, the opposite of migraine sufferers who typically want to lie still in the dark.
Misdiagnosis and the suicide headache nickname 50:00
Cluster headache has been nicknamed suicide headache both because of the pain intensity and because attacks can recur up to eight times a day, with cluster periods lasting weeks or months, sometimes without any break at all in the chronic form. It runs in families, with first-degree relatives at higher risk, and it is frequently misdiagnosed because its seasonal timing mimics sinus infections or allergies, leading some patients to receive unnecessary antibiotics, allergy shots, or even dental and sinus surgery. A detailed patient questionnaire can help flag the condition early, and because it is so severe, patients who report symptoms matching cluster headache are typically seen more quickly.
Treating during an active attack 55:31
Seeing a cluster headache patient while they are actively suffering can help clarify diagnosis and treatment, since these patients often need three coordinated approaches: an acute treatment to rapidly stop an attack in progress, a preventive treatment to reduce how often attacks occur, and a transitional treatment to bridge the gap while preventive medications, which can take weeks or months to become effective, start to work. Lifestyle measures also matter, including avoiding alcohol and foods containing nitrates, skipping daytime naps, and treating sleep apnea if present, since the resulting drop in oxygen, hypoxia, can be linked to triggering attacks.
Risk Factors That Drive Migraine Progression 57:00
Migraine has its own set of identified risk factors, separate from cluster headache. Having one or more migraine attacks per week increases the risk of the condition becoming more frequent over time, a process sometimes called chronification. Stressful life events, sleep disturbances such as insomnia or sleep apnea, and coexisting mood disorders like depression and anxiety all raise risk, and mood disorders have a two-way relationship with migraine. Overusing acute pain medications, including NSAIDs, acetaminophen, triptans, barbiturate combinations like Fioricet, and opioids, two or more days a week over time can itself trigger more frequent headaches. Other pain disorders and poorly treated nausea during attacks also raise risk.
Obesity's Outsized Effect on Migraine 59:00
Obesity stands out as a major, modifiable risk factor. People classified as morbidly obese face five times the risk of more frequent migraine, while those in the 30-to-35 BMI range face roughly double the risk. Weight loss, whether surgical or non-surgical, has been shown in studies to improve migraine for many, though not everyone. The likely mechanism is multifactorial, tied partly to migraine's own pro-inflammatory component and possibly shared pathways with obesity-related inflammation.
Different Prevention Logic for Cluster Versus Migraine 1:01:30
For cluster headache, prevention centers on the underlying mechanisms tied to the sleep-wake cycle, the hypothalamus, and the pineal gland, which produce a striking seasonal and daily periodicity. Patients often notice attacks flaring at the spring and fall clock changes, and one patient from Australia reliably gets attacks when seasonal shifts occur during travel. Controlling a person's light environment might reduce exposure to seasonal triggers but wouldn't eliminate cluster attacks outright. Migraine prevention instead focuses on addressing broader risk factors to lower overall probability of attacks, since it has fewer clear-cut acute triggers.
Tracking Diaries to Find Individual Triggers 1:04:30
Rather than relying on unproven testing, the approach mirrors an elimination-diet strategy: watch closely, remove suspected triggers one at a time, and note what changes. Patients are asked which one or two questions matter most to them before each visit, and lifestyle guidance covers regular meals, sleep, hormones, exercise, and trigger burden. A month-long headache diary often reveals patterns patients miss themselves, such as weekend attacks caused by a cluster of changes: harder exertion during the week followed by an endorphin drop, later bedtimes and wake times on Friday and Saturday, and delayed morning caffeine. Menstrual migraine diaries can reveal consistent timing relative to the cycle, allowing preemptive treatment to start in advance of expected attacks.
Who Actually Needs Preventive Medication 1:12:00
Preventive therapy aims to reduce frequency, intensity, or duration of attacks, improve responsiveness to acute treatments, slow disease progression, and ease anticipatory anxiety between attacks. Roughly 40 percent of people with migraine meet criteria for prevention, yet only about 16 to 17 percent actually receive it, a gap driven by clinicians not recognizing the need and by economic barriers. For cluster headache, the vast majority of patients need preventive therapy unless the cluster period lasts only about a week. Tension-type headache prevention depends on whether it's episodic (fewer than 15 days a month) or chronic (15 or more days a month).
Beta Blockers and Antidepressants for Prevention 1:16:30
Beta blockers such as propranolol and timolol, both FDA-approved for migraine, work through an unclear mechanism likely tied to the sympathetic nervous system, but carry cautions for people with asthma and can lower blood pressure or heart rate. Antidepressants like amitriptyline and nortriptyline are used at doses far lower than those needed to treat depression, and their main side effect, drowsiness, can actually help patients who struggle with insomnia. Both drug classes were originally designed for other conditions and only later found useful for migraine through observation, a point worth stressing since patients often wrongly assume being prescribed them implies a diagnosis of high blood pressure or depression.
Anti-Seizure Drugs and the CGRP Breakthrough 1:20:00
Anti-seizure medications such as topiramate (Topamax) and valproic acid (Depakote) are also FDA-approved for migraine prevention, working through effects on glutamate, the brain's excitatory neurotransmitter, and GABA, its suppressive counterpart, though each carries its own side effects. Because most migraine patients are women of reproductive age, prevention planning must account for contraceptive use and pregnancy safety. The conversation then turns toward CGRP, calcitonin gene-related peptide, monoclonal antibodies, a newer drug class that produced a dramatic success for a patient enrolled early in a clinical trial, setting up a deeper explanation of migraine's underlying biology.
The neurovascular basis of migraine pain 1:24:01
The brain itself cannot feel pain, but the coverings around it, called the meninges, along with the blood vessels inside them, are packed with pain-sensitive nerve endings. The main nerve carrying this pain signal is the trigeminal nerve. Older thinking from the 1940s treated migraine as a purely vascular problem, with blood vessels widening during pain and narrowing during recovery, but decades of research since have shown this model was too simple. Migraine is now understood as a neurovascular event, meaning both the nervous system and the blood vessels in the skull are involved. Pain signals from the meninges and blood vessels travel along the trigeminal nerve to a spot in the brainstem called the trigeminal nucleus caudalis, and nerves from the upper neck, C1 through C3, feed into that same brainstem area, which explains why migraine and tension headache so often come with neck pain. From the brainstem, signals move to the thalamus and then to the sensory cortex. Along the way, a cascade of chemical messengers gets released, including substance P and calcitonin gene-related peptide, or CGRP, and this cascade also triggers the autonomic symptoms seen in migraine and cluster headache, such as tearing, eye redness, and nasal congestion.
Sensitization and the warning sign of allodynia 1:26:31
When these nerves keep firing, patients can develop what is called central sensitization, and one clinical marker of this is allodynia, an uncomfortable reaction to things that normally shouldn't hurt, like putting hair into a tight ponytail or brushing it. This tends to appear thirty to sixty minutes into a migraine, and once it kicks in, triptans become less effective, which is why knowing whether a patient experiences allodynia matters for deciding when to treat.
CGRP and the rise of monoclonal antibody treatments 1:28:30
Studies measuring blood from the jugular vein found CGRP levels rise during migraine attacks, and when sumatriptan or Imitrex was given, those elevated CGRP levels normalized. That finding led directly to a new class of drugs, CGRP antagonists, split into large monoclonal antibodies and smaller molecules called gepants. Three of the monoclonal antibodies are self-injected, similar to an EpiPen, with a roughly 28-day half-life, so they are given monthly, while one version is given as a quarterly infusion. These drugs have been a major improvement in clinical practice, working for up to 60 percent of migraine patients, though response varies widely, some improving within a month and others taking three to four months. Failing one drug in the class does not predict failure on another, since there are no biomarkers to tell in advance which one will work, similar to how PCSK9 inhibitors behave in cholesterol treatment. Cost is a serious barrier, often thousands of dollars a year, with insurance coverage varying so much that some patients travel abroad to buy the medication more cheaply, echoing the story of diabetic patients flying to Europe for cheaper insulin.
Calcium channel blockers and Botox 1:38:30
Calcium channel blockers, normally blood pressure medications, are used more for cluster headache prevention than migraine, sometimes at very high doses, such as one patient on over a thousand milligrams of verapamil, monitored closely with EKGs. Botox's use in migraine was a serendipitous discovery by plastic surgeon Bill Binder, whose cosmetic patients reported fewer headaches, leading to its approval specifically for chronic migraine, defined as fifteen or more headache days a month. Botox does not work well for tension headache. It is injected in a standardized pattern called the PREEMPT protocol across the forehead, temples, back of the head, neck, and shoulders, working by interfering with SNARE and SNAP proteins and CGRP release rather than through any cosmetic effect.
Rescue treatments during an attack 1:43:32
For acute attacks, doctors use non-migraine-specific drugs like acetaminophen and NSAIDs, but opioids and barbiturate combination drugs like Fiorinal are avoided as much as possible because even occasional use raises the risk of medication overuse and chronic migraine. Triptans, developed in the mid-1990s starting with sumatriptan, target specific serotonin receptors and were a major advance over the older ergotamines. There are seven triptans total, and their effectiveness varies by individual rather than by how recently they were developed, with differences in speed of onset, side effects like flushing or warmth, and formulation, including tablets, melts, nasal sprays, and injections. Injectable sumatriptan works fastest, useful for cluster headache attacks where pain relief can come in about nine minutes, while nasal sprays vary in absorption, with newer formulations like zolmitriptan nasal spray or zavegepant offering better bioavailability than generic sumatriptan spray. Success is generally measured by pain relief and functional improvement within two hours, along with how often headache returns within 24 hours. Neuromodulation devices, using magnetic or electrical stimulation on nerves like the trigeminal nerve above the eyebrow, offer another option by suppressing pain signals before they travel centrally.
Neuromodulation Devices For Migraine 1:53:30
Several external devices can stimulate nerves to prevent or treat migraine without being implanted. One example is Nerivio, an armband controlled by a phone app that stimulates a nerve in the arm to trigger the brain's own pain-reducing mechanisms; it is approved for both prevention and acute treatment. Devices are FDA cleared rather than FDA approved like drugs, and there are no head-to-head comparisons between them. Costs vary: some devices are purchased outright, some are leased monthly, and others are billed per number of treatments, sometimes with insurance reimbursement. Many patients never learn these options exist, and some prefer them over medication, including people trying to conceive, since the devices are not associated with drug exposure even though they haven't been formally studied in pregnancy.
Cannabis And Unanswered Questions 1:57:02
A large study at this academic headache program found roughly a third of patients use cannabinoids, but standardizing dosing and formulation is nearly impossible in real-world use, making it hard to know whether benefits come directly from treating headache or indirectly from improved sleep or anxiety. Because THC is a Schedule I substance, controlled trials are difficult to run, though one study has looked at a single formulation for acute treatment, and a company is planning larger future trials.
Living With Migraine Long Term 1:59:01
Patients should track their headaches, embrace lifestyle changes, and understand that prevention is a partnership, not a service where a doctor dictates and results appear overnight. Preventive medications can take weeks or months, sometimes requiring more than one drug, and acute treatments may need backups or, for a migraine lasting beyond three days, intravenous rescue therapy.
When Headache Signals Something Else 2:01:32
New or changed headache patterns, fever, neck stiffness, unintended weight loss, neurological symptoms like weakness or vision loss, onset after age fifty, or a sudden thunderclap peak all warrant medical attention. CSF leaks, whether from trauma or spontaneous, can cause positional headaches, worsening through the day, or pain between the shoulder blades, and are notoriously hard to diagnose, prompting dedicated CSF programs at places like Duke.
AI-generated summary. It can be wrong or incomplete - check anything that matters against the original.
